Pathogenesis for mice of Coxsackie A virus, type 16.
D000273:Adipose Tissue / Q000382:microbiology; D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D000956:Antigens, Viral / Q000302:isolation & purification; D001921:Brain / Q000382:microbiology; D003384:Coxsackievirus Infections; D004770:Enterovirus / Q000302:isolation & purification / Q000472:pathogenicity*; D005260:Female; D005455:Fluorescent Antibody Technique; D006321:Heart / Q000382:microbiology; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007928:Lethal Dose 50; D008099:Liver / Q000382:microbiology; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009132:Muscles / Q000382:microbiology; D009220:Myositis / Q000382:microbiology; D009336:Necrosis / Q000382:microbiology; D010243:Paralysis / Q000382:microbiology; D011239:Prednisolone / Q000494:pharmacology; D013231:Steatitis / Q000382:microbiology
D000956:Antigens, Viral; D011239:Prednisolone